Ke AB[au] - Search Results

Year	Number of Results
2012	1
2013	3
2014	6
2015	2
2016	1
2018	1
2019	1
2020	2
2021	1
2022	2

1

Pharmacometrics in pregnancy: An unmet need.

Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Ke AB, et al. Annu Rev Pharmacol Toxicol. 2014;54:53-69. doi: 10.1146/annurev-pharmtox-011613-140009. Annu Rev Pharmacol Toxicol. 2014. PMID: 24392692 Review.

2

Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?

Johnson TN, Ke AB. Johnson TN, et al. Among authors: ke ab. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S83-S93. doi: 10.1002/jcph.1834. J Clin Pharmacol. 2021. PMID: 34185901 Review.

3

Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.

Ke AB, Greupink R, Abduljalil K. Ke AB, et al. CPT Pharmacometrics Syst Pharmacol. 2018 Feb;7(2):103-110. doi: 10.1002/psp4.12274. Epub 2018 Jan 31. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 29349870 Free PMC article. Review.

4

Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction.

Oggianu L, Ke AB, Chetty M, Picollo R, Petrucci V, Calisti F, Garofolo F, Tongiani S. Oggianu L, et al. Among authors: ke ab. CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):77-86. doi: 10.1002/psp4.12480. Epub 2020 Jan 11. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31808613 Free PMC article.

5

A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.

Mendes MS, Hatley O, Gill KL, Yeo KR, Ke AB. Mendes MS, et al. Among authors: ke ab. Eur J Pharm Sci. 2020 Jul 1;150:105355. doi: 10.1016/j.ejps.2020.105355. Epub 2020 May 18. Eur J Pharm Sci. 2020. PMID: 32438273

6

Evaluation of Maternal Drug Exposure Following the Administration of Antenatal Corticosteroids During Late Pregnancy Using Physiologically-Based Pharmacokinetic Modeling.

Ke AB, Milad MA. Ke AB, et al. Clin Pharmacol Ther. 2019 Jul;106(1):164-173. doi: 10.1002/cpt.1438. Epub 2019 May 6. Clin Pharmacol Ther. 2019. PMID: 30924921

7

Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.

Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Ke AB, et al. Clin Pharmacol Ther. 2014 May;95(5):473-6. doi: 10.1038/clpt.2014.41. Clin Pharmacol Ther. 2014. PMID: 24747234

8

Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations.

Oggianu L, Di Dato G, Mangano G, Rosignoli MT, McFeely S, Ke AB, Jones HM, Comandini A. Oggianu L, et al. Among authors: ke ab. Clin Transl Sci. 2022 Jun;15(6):1417-1429. doi: 10.1111/cts.13253. Epub 2022 Mar 2. Clin Transl Sci. 2022. PMID: 35233913 Free PMC article.

9

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

Small DS, Ke AB, Hall SD, Mantlo N, Rotelli M, Friedrich S. Small DS, et al. Among authors: ke ab. J Clin Pharmacol. 2015 Jul;55(7):757-67. doi: 10.1002/jcph.472. Epub 2015 Feb 20. J Clin Pharmacol. 2015. PMID: 25651523

10

Wortmannilactones I-L, new NADH-fumarate reductase inhibitors, induced by adding suberoylanilide hydroxamic acid to the culture medium of Talaromyces wortmannii.

Liu WC, Wang YY, Liu JH, Ke AB, Zheng ZH, Lu XH, Luan YS, Xiu ZL, Dong YS. Liu WC, et al. Among authors: ke ab. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5328-5333. doi: 10.1016/j.bmcl.2016.09.032. Epub 2016 Sep 14. Bioorg Med Chem Lett. 2016. PMID: 27671500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results